




# NovaUCD

## Technology Licensing Opportunity



### sanaPerOx

- A novel strategy for intestinal health



#### Opportunity:

sanaPerOx is a controlled release  $H_2O_2$  generator targeted to specific areas in the GI tract. Low concentrations of  $H_2O_2$  do not cause oxidative damage, but instead promote gut health. The  $H_2O_2$  generator can strengthen the physical barrier between host and microbiota to enhance mucosal healing, while modulating the microbiota composition for improved homeostasis and pathogen defence. A controlled drug delivery system renders the  $H_2O_2$  generator inactive until it reaches a target location within the GI tract. Activation generates  $H_2O_2$  together with a prebiotic.

#### Applications:

- Improves gut and digestive health
- IBD as a treatment after acute colitis flare and to maintain remission.
- Orphan indications i.e. Paediatric IBD, genetic diseases with deficiency in  $H_2O_2$  generation.

#### Key Features/Advantages:

- Strengthens the intestinal barrier function and stimulates mucosal secretion, promoting gut healing
- Modulates the microbiome and promotes a protective microbiota composition
- Oral Drug Delivery System with controlled release technology using well characterized compounds with GRAS status

#### Value Proposition:

New therapeutic strategy for gastrointestinal disease. sanaPerOx supports mucosal healing and a balanced, protective microbiota composition

#### Market:

Gut and digestive health  
Inflammatory bowel disease  
Orphan indications: Paediatric IBD  
Genetic diseases with  $H_2O_2$  deficiency

#### Lead Inventor:

Prof Ulla Knaus, School of Medicine, Conway Institute, UCD

#### IP Status/Publication:

National filings in US and Japan, regional filing in Europe  
Patent WO 2017/174744A1  
Published 12/10/2017



#### Contact:

Dr Ena Walsh  
Case Manager  
Knowledge Transfer  
t: + 353 1 716 3706  
e: ena.walsh@ucd.ie

FUNDERS:

